All-In Podcast – Episode Summary Episode: "Are Psychedelics the Key to Living Forever? (ft. Bryan Johnson)"
Date: March 26, 2026
Guests: Bryan Johnson
Hosts: All-In Podcast team (Chamath, Jason, Sacks & Friedberg)

Overview

This episode features longevity entrepreneur Bryan Johnson, who shares his recent and profound experiences with psychedelics—particularly 5-MeO-DMT—and discusses experimental approaches to brain and body rejuvenation. The conversation delves into the intersection of psychedelics, neurobiology, and the science of longevity, while exploring both the breakthroughs and risks associated with these frontiers. The hosts and Johnson reflect on the personal, professional, and societal implications of transformative therapies.

Key Discussion Points & Insights

1. Why Experiment with Psychedelics for Longevity?

• Initial Motivation (00:58):
  • Bryan Johnson began with conventional longevity interventions (exercise, nutrition, sleep, hyperbaric oxygen therapy, sauna, rapamycin, metformin).
  • Psychedelics were not initially on the radar as an anti-aging tool; viewed more as ancient or therapeutic for depression/anxiety.
  • Preclinical evidence in mice showed psilocybin could impact aging and inflammation.

“We just went down the list from top performing on down... We never actually had on our radar psychedelics... But we found preclinical evidence in mice on psilocybin. We thought, that's interesting.”
— Bryan Johnson, [01:00]

2. Profound 5-MeO-DMT Experience

• Live Experimentation & Subjective Report (02:14–05:19):
  • Johnson describes a 48-hour post-experience state after a high-dose 5-MeO-DMT session.
  • The experience is “impossible to explain,” described as immersion in “raw consciousness and raw intelligence” with infinite dimensions.
  • Distinct from visual psychedelics like DMT; 5-MeO-DMT is non-visual, focusing on dissolution of ego and self.
  • Peak moments involve either panic (fear of ego death/madness) or complete surrender, leading to bliss and euphoria.

“It was incredibly hard because you get blasted into this space... It’s going to break your brain... You have to release self, ego, control... And then when you do that, it opened up this unimaginable bliss and euphoria... This is without question the most dynamic experience I’ve ever experienced as a human.”
— Bryan Johnson, [02:26–05:19]

3. Neurobiology of Psychedelics

• Default Mode Network & Rewiring the Brain (06:11–09:06):
  • 5-MeO-DMT and psilocybin function by dampening or annihilating the brain’s default mode network (DMN).
  • DMN is responsible for “self” and ego; as people age, DMN creates rigid thought patterns (the “ruts” of adulthood).
  • Psychedelics disrupt and randomize these patterns, promoting neuroplasticity and potentially a more open, childlike mind.

“Kids don't have this rumination loop. Their default mode network is quiet. And as you age, you basically build up this default mode network into more stiffer patterns... When you do something like psilocybin, it basically ... scrambles the traffic patterns.”
— Bryan Johnson, [06:41–07:52]

• Clinical & Personal Data (09:43):
  • After psilocybin, Johnson observes a metabolic reset in brain chemistry, unusually improved blood glucose, and changes in the microbiome.
  • 5-MeO-DMT produced a more profound and thorough reset of DMN than psilocybin.

“Psilocybin dampens it, like it softens it. But this thing just annihilated my default mode.”
— Bryan Johnson, [10:05–10:34]

4. Persistent Psychological Changes

• Restored Childlike Outlook (10:55–12:56):
  • Post-5-MeO, Johnson reports laughing in dreams (“a characteristic of a child”), spontaneous excitement, more humor, and better conflict resolution.

“I just felt absolutely, like, no need to escalate or to defend... It was a breakthrough in our relationship.”
— Bryan Johnson, [12:11]

• Personal Relationships and Self-Reflection (13:07–15:01):
  • Prior experiences with hallucinogenics were mostly therapeutic, linked to major life changes.
  • Contrasts the transient effects of ketamine with the profound transformation of 5-MeO.

5. Data, Measurement, and Safety

• Objective Mapping (13:55–14:57):

  • Johnson has collected structural and functional MRIs, brain interface data (Kernel), and EEG before/during/after psychedelic sessions.
  • Initial findings show “dramatic restoration of youthful brain patterns” post-psilocybin.

• Safety and Risks (16:04–17:27):

  • Recognizes real risks of psychosis and scarred experiences; emphasizes importance of “set and setting” and supervised, quantified dosing.
  • Need for rigorous frameworks to make psychedelics safe and clinically useful.

“If we do create a safety structure around it, they could deliver the benefits people want with less risk... It deserves all the caution in the world.”
— Bryan Johnson, [16:28]

6. Philosophical and Societal Implications

• Self, Identity, and Values (21:01–22:16):
  • Questions if rapid, drug-induced neural rewiring creates a “new person.”
  • Explores moral questions about shifting values pre/post transformation.

“If I go in and take a drug and in a few hours rewire all my neurons, am I the same person?”
— Host, [21:03]

• Impact on Leadership/Enterprise (19:34–20:57):
  • Discusses trend of entrepreneurs abandoning companies after psychedelic revelations.
  • Some investors now put anti-psychedelic clauses in deals to limit founder risk.

7. Longevity Frontier: New Therapies

• Beyond Psychedelics (26:23–34:09):
  • Bryan details upcoming or experimental therapies:
    • Cell and Gene Therapies: Not quite ready for wide use; in the pipeline.
    • Mitochondrial Rejuvenation: Including mitochondrial transplants (possibly from family members with “younger” mitochondria); compared to “blood boy” concept.
    • Organoid Testing: Using his own stem-cell-derived tissue to test drug effects in vitro before human trials.
    • Plasmid and FoxO3 Gene Therapy: Potential for tissue regeneration and rejuvenation.
    • Investment in New Limit and Yamanaka Factor Alternatives: Accelerating cellular rejuvenation; concerns with tumorigenesis and need for precise dosing and safety switches.

“We have our first mitochondrial therapy lined up... I will do a blood draw in the next week or two. They'll spin up and then they'll do it.”
— Bryan Johnson, [27:13–28:38]

“We took my IPSCs... Now we're doing in dish [organoids]... So that's interesting because now I have to do this old school methodology, like put it in my body, wait to see what happens.”
— Bryan Johnson, [30:48–31:58]

8. The Psychological Edge of Psychedelics

• Role in Maintaining Youthful Disposition (35:24–37:18):
  • Longevity interventions affect the body, but psychedelics may be unique in restoring “psychological youthfulness” and a can-do mindset as people age.
  • Johnson felt “30–40 years of psychological rejuvenation” after 5-MeO.

9. Societal and Ethical Dimensions

• Abundance, Happiness, and Social Change (34:09–35:06):
  • Advances in health, therapy, and increased abundance could create broad shifts in attitudes, reduce conflict driven by internal unhappiness, and improve society’s overall wellbeing.

Memorable Quotes & Moments

• On Ego Dissolution:

  "You have to release all attachment, all preconditions, all want, all desire. You have to release self, ego, control... And when you do that, it opened up this unimaginable bliss and euphoria."
  — Bryan Johnson, [04:26]

• On Safety:

  "...It needs to be done properly with a licensed professional. It needs to be done carefully. The person needs to be in the right state... It deserves all the caution in the world."
  — Bryan Johnson, [16:04]

• On Profound Efficacy:

  "If I just subjectively compare my experience with 5MEO to having a better diet and exercising every day and sleeping well and doing the sauna and doing hyperbaric oxygen therapy, this was more efficacious than all of them."
  — Bryan Johnson, [17:46]

• On Identity:

  "If I go in and take a drug and in a few hours rewire all my neurons, am I the same person?"
  — Host, [21:03]

• On Future of Rejuvenation:

  "It is the most profound, I think, technology that humanity is dealing with today besides AI...”
  — Host, [33:10]

Timestamps for Important Segments

• Opening & Motivation for Psychedelics: [00:58]
• Description of 5-MeO-DMT experience: [02:14–05:19]
• Default Mode Network discussion: [06:11–09:06]
• Subjective and clinical effects of psilocybin: [09:43]
• Translation to everyday life and relationships: [10:55–12:56]
• Data collection & initial results: [13:55–15:01]
• Risks and safety in psychedelics: [16:04–17:27]
• Philosophical/identity implications: [21:01–22:16]
• Therapy pipeline (mitochondrial, gene, cell, organoid): [26:23–34:09]
• Role of psychedelics in psychological youthfulness: [35:24–37:18]

Conclusion

Bryan Johnson’s blend of quantified self-experimentation and philosophical curiosity pushes the boundaries of what’s possible in the realms of psychedelics and longevity. This dynamic, data-driven conversation dissects the immediate effects and long-term implications of mind-bending therapies, robustly reflecting on how science, identity, psychology, and society may all be transformed by the tectonic shifts now underway in health and biotechnology.